Toxicity manifesting as cosmetic hair alterations during erlotinib treatment

Acta Oncologica

Volumn 50, Issue 1, 2011, Pages 146-148

  Kudo, Kenichiro ^a   Fujiwara, Keiichi ^a   Tsushima, Mizuho ^a   Mizuta, Makoto ^a   Matsuo, Kiyoshi ^a   Yonei, Toshiro ^a   Sato, Toshio ^a  

^a NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB;

ADVANCED CANCER; AGED; CANCER GROWTH; CASE REPORT; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HAIR GROWTH; HUMAN; HYPERTRICHOSIS; LETTER; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERTRICHOSIS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 78650573484     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.509107     Document Type: Letter

References (9)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
2. Fox LP. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology 2006; 20:26-34.
3. Braiteh F, Kurzrock R, Johnson FM. Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib. J Clin Oncol 2008;26:3460-2.
4. Alexandrescu DT, Kauffman CL, Dasanu CA. Persistent hair growth during treatment with the EGFR inhibitor erlotinib. Dermatol Online J 2009;15:4.
5. M àr quez G, Herrera-Acosta E, Vidal I, Galvany L, Iglesias M, Umbert P. A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva). Int J Dermatol 2009;48:97-8.
6. Montagut C, Grau JJ, Grimalt R, Codony J, Ferrando J, Albanell J. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. J Clin Oncol 2005;23:5273-5. (Pubitemid 46224050)
7. Gryngarten M, Bedecarrà s P, Ayuso S, Bergadà C, Campo S, Escobar ME. Clinical assessment and serum hormonal profi le in prepubertal hypertrichosis. Horm Res 2000;54:20-5. (Pubitemid 32153927)
8. Hansen LA, Alexander N, Hogan ME, Sundberg JP, Dlugosz A, Threadgill DW, et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am J Pathol 1997;150:1959-75. (Pubitemid 27233070)
9. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefi tinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37. (Pubitemid 41540110)